Atea Pharmaceuticals, Inc. (AVIR) — DEFA14A Filings
All DEFA14A filings from Atea Pharmaceuticals, Inc.. Browse 4 DEFA14A reports with AI-powered summaries and risk analysis.
DEFA14A Filings (4)
-
Atea Pharmaceuticals Files Proxy Statement
— Apr 3, 2025 Risk: low
Atea Pharmaceuticals, Inc. filed a DEFA14A on April 3, 2025, indicating it is soliciting materials under Rule 14a-12. The filing does not require a fee, as it w -
Atea Pharma Proxy Solicitation Filing
— Apr 1, 2025 Risk: low
Atea Pharmaceuticals, Inc. filed a DEFA14A on April 1, 2025, related to a solicitation of proxies. The filing indicates that the company is seeking shareholder -
Atea Pharmaceuticals Files Proxy Statement
— Mar 26, 2025 Risk: low
Atea Pharmaceuticals, Inc. filed a DEFA14A on March 26, 2025, indicating it is soliciting material under Rule 14a-12. The filing pertains to their proxy stateme -
Atea Pharmaceuticals Files Proxy Supplement
— Jun 4, 2024 Risk: low
Atea Pharmaceuticals, Inc. filed a Definitive Additional Materials filing (DEFA14A) on June 4, 2024, to supplement its proxy statement regarding the election of
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX